When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Última revisão: 16 Mar 2025
Última atualização: 07 Feb 2025

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • lesão pigmentada alterada (sinais do ABCDE)
  • lesão melanocítica que não se assemelha a nevos melanocíticos circundantes ("patinho feio")
  • sangramento espontâneo ou ulceração de uma lesão pigmentada
  • sintomas constitucionais
  • sinal ungueal: melanoníquia estriada persistente em uma única unha
  • sinal ungueal: sinal de Hutchinson
  • achados dermatoscópicos atípicos
  • linfadenopatia fixa
  • metástases em trânsito

Fatores de risco

  • exposição ao sol
  • história familiar de melanoma
  • história pessoal de melanoma
  • história pessoal de câncer de pele (inclusive danos actínicos)
  • história de nevos atípicos
  • Tipo de pele I ou II (pele branca) de Fitzpatrick
  • cabelo ruivo ou louro
  • alta densidade de sardas
  • uso de câmaras de bronzeamento
  • olhos claros
  • números elevados de nevos melanocíticos com aparência benigna
  • nevos congênitos grandes
  • imunossupressão
  • xeroderma pigmentoso

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • dermatoscopia
  • biópsia de pele
  • imuno-histoquímica

Investigações a serem consideradas

  • biópsia do linfonodo sentinela
  • tomografia computadorizada (TC) do tórax/abdome/pelve
  • PET do corpo inteiro
  • imagens do cérebro (tomografia computadorizada [TC] ou ressonância nuclear magnética [RNM])
  • análise mutacional em BRAF
  • Análise mutacional de NRAS
  • lactato desidrogenase (LDH) sérica

Novos exames

  • Análise mutacional de CDKN2A

Algoritmo de tratamento

Colaboradores

Autores

Yin Wu, MRCP(UK), PhD

Wellcome Trust Clinical Research Career Development Fellow and Honorary Consultant Medical Oncologist

Peter Gorer Department of Immunobiology

King's College London

Department of Medical Oncology

Guy's and St Thomas' NHS Foundation Trust

London

UK

Declarações

YW is funded by the Wellcome Trust, and consults for PersonGen Therapeutics, and Biotherapeutics.

Amanda Fitzpatrick, MRCP(UK), PhD

Medical Oncologist and Honorary Senior Lecturer

Guy's Cancer Centre

King's College

London

UK

Declarações

AF declares she has no competing interests.

Pablo Fernandez-Peñas, MD, PhD, FACD

Professor of Dermatology

The University of Sydney

Sydney

Australia

Declarações

PF-P declares that he has no competing interests with the topic Melanoma. PF-P has advisory roles with Amgen, Boehringer Ingelheim, Bristol Meyers Squibb, Leo, Novartis, Lilly, Abbvie, Janssen, Celgene (psoriasis, atopic eczema, hidradenitis), Roche, Merck Sharp & Dohme, Sun Pharmaceuticals, Novartis, and Sanofi. He has been paid to do research for Incyte Europe Sarl, and clinical trials for Arena, Akaal Pharma, Xoma, Kyowa Hakko Kirin, AbbVie, OncoSec, Lilly, CSL Behring, Boehringer Ingelheim, Pfizer, mRage, Eisai, Jiansu Hengrui, Bristol-Myers Squibb, Sun Pharma, Novartis, Roche, Galderma, Regeneron, UCB, GlaxoSmithKline, and Amgen.

Agradecimentos

Dr Yin Wu, Dr Amanda Fitzpatrick, and Dr Pablo Fernandez-Peñas would like to gratefully acknowledge Dr Prachi Bhave, Dr Robyn P.M. Saw, Dr Sophie E. Papa, Dr Alexander M. Menzies, Dr Philip Friedlander, Dr Hobart W. Walling, and Dr Brian L. Swick, previous contributors to this topic.

Declarações

PB has received honoraria from Bristol-Myers Squibb, MSD and Novartis and sponsorship from MSD and Novartis. RPMS is on the advisory board for Novartis, MSD, and Qbiotics and has previously been on the advisory board for Amgen; he has received honoraria from BMS and Novartis. SEP has received honoraria from BMS, MSD, and Novartis to attend conferences; she has participated in advisory boards for BMS, MSD, Amgen, Roche, and GSK. AMM has received honoraria from Novartis and BMS; he is on the advisory boards of MSD and Chugai. PF is a consultant for Genentech. HWW and BLS declare that they have no competing interests.

Revisores

David Cassarino, MD, PhD

Assistant Professor

Department of Pathology and Laboratory Medicine

University of California

Los Angeles

CA

Declarações

DC declares that he has no competing interests.

James DeBloom, MD

Dermatologist/Dermatologic Surgeon

President of the South Carolina Skin Cancer Center

Greenville

SC

Declarações

JB declares that he has no competing interests.

Mai Brooks, MD, FACS

Associate Director

JCCC Women's Cancers Program Area

Jonsson Comprehensive Cancer Center at UCLA

Los Angeles

CA

Declarações

MB declares that she has no competing interests.

Karol Sikora, MA, MBBCh, PhD, FRCR, FRCP, FFPM

Medical Director

CancerPartnersUK

London

UK

Declarações

KS declares that he has no competing interests.

O uso deste conteúdo está sujeito ao nosso aviso legal